NCT05195294View on ClinicalTrials.gov

Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Hepatocellular CarcinomaLiver Cancer, AdultLiver Cell Carcinoma
Interventions
BIOLOGICAL

LioCyx-M

HBV antigen specific TCR redirected T cells

DRUG

Lenvatinib

12 mg once daily for patients ≥60 kg, 8 mg for patients \<60kg by oral

All Listed Sponsors
lead

Lion TCR Pte. Ltd.

INDUSTRY